Recently, LSINCT5 overexpression has been identified in lung cancer [13], hepatocellular carcinoma [14], bladder cancer [15], gastric cancer [16,17] and colorectal cancer [16]. This evidence concerns the gene LSINCT5 and urinary bladder carcinoma.